NetFlix Inc vs Sanofi SA — how do they compare? NetFlix Inc trades at $68.13 (market cap $281.48B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: NetFlix Inc is far larger — about 2.7× Sanofi SA's market cap, and Sanofi SA pays a 5.5% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| NFLX | SNY | |
|---|---|---|
Market Cap | $281.48B | $104.83B |
Sector | Consumer Cyclical | Health |
52-Week High | $126.33 | $52.34 |
52-Week Low | $67.60 | $41.33 |
Enterprise Value | $286.66B | $121.32B |
Dividend Yield | — | 5.5% |
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) is trading at $68.95, down 7.26% over 24 hours and approaching its 52-week low. The stock shows bearish technical signals with oversold RSI levels, while fundamentals remain strong with Q1 2026 EPS beating expectations at $1.23 versus $0.763. Revenue grew to $45.18B in 2025 with a net income margin of 24.3%, though valuation ratios like P/E of 21.26 and P/S of 6.02 suggest moderate pricing. Recent news highlights stock declines despite business growth, with focus on advertising expansion and content performance.
The outlook for NFLX is mixed; strong earnings and ad-tier scalability offer upside, but technical weakness and competitive pressures pose risks. Analysts maintain a buy consensus with a $90.47 price target, implying significant potential appreciation. Key risks include market sentiment shifts and execution challenges in new revenue streams, requiring careful monitoring of quarterly results and subscriber trends.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →